Has Bogdana Schmidt, MD received payments from drug or device companies?

Yes. Drug and device makers reported $35,995 in general payments to Bogdana Schmidt, MD across 76 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bogdana Schmidt, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bogdana Schmidt, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bogdana Schmidt, MD

Urology · Stanford, CANPI 1386987865

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 51.8% of the total. 2025 is the largest year on record at $18,348, more than ten times the $119 reported in 2021. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$35,995in general payments, 2019–2025

Across 76 payments — averaging $473.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Ferring Pharmaceuticals Inc.$19K
Intuitive Surgical$7K
Urogen Pharma, Inc.$4K
Janssen Global Services, LLC$3K
Janssen Scientific Affairs, LLC$1K
Johnson & Johnson$965
plus $984 from 6 others

$325,906in research payments, 2019–2025

Across 56 payments — averaging $5819.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Research & Development, LLC$305K
Ferring Pharmaceuticals AS$21K

What the payments were for

Consulting fees$15,59843%
Speaking & faculty fees$10,05028%
Travel & lodging$3,48510%
Food & beverage$2,8638%
Education$4,00011%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Ferring Pharmaceuticals Inc.	20	$18,645
Intuitive Surgical	27	$7,199
Urogen Pharma, Inc.	4	$4,087
Janssen Global Services, LLC	3	$3,084
Janssen Scientific Affairs, LLC	4	$1,031
Johnson & Johnson	3	$965
Janssen Research & Development, LLC	5	$280
Coloplast	3	$269
Boston Scientific	4	$234
Fennec Pharmaceuticals, Inc.	1	$137
Teleflex LLC	1	$36
Myriad Genetic Laboratories, Inc.	1	$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,995 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$118,505

Medicare patients

187

Services billed

495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	16	$7,319
EliquisApixaban	11	$5,228
Tamsulosin Hcl	23	$168
Oxybutynin Chloride	14	$44

Paid to pharmacies, not to this prescriber.

Other urology in Stanford

Benjamin ChungStanford$80K
Stephen FreedlandWest Hollywood$1.9M
Arie BelldegrunLos Angeles$1.8M
Mihir DesaiLos Angeles$1.5M
Steven WilsonIndio$1.1M
Stuart HoldenLos Angeles$1.1M
Elward CrawfordSan Diego$849K
Edward UchioOrange$849K
Victor ChingUpland$809K
Jaime LandmanOrange$657K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →